Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201508
- Shanghai Public Health Clinical Center
-
Shanghai, Shanghai, China
- Shanghai Public Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China;
- Participants aged over 18;
- Written the informed consent.
Exclusion Criteria:
- Hypersensitivity to chloroquine or hydroxychloroquine;
- Women during pregnancy;
- Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
- Participants with retinal disease, hearing loss;
- Participants with severe neurological and mental illness;
- Subjects were considered to be unable to complete the study, or not suitable for the study by researchers.
Exit criteria:
- Subjects asked to withdraw the study
- Subject will benefit if withdraw according to researchers' suggestions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hydroxychloroquine and conventional treatments
After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
|
Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
|
|
No Intervention: Conventional treatments
After randomization, subjects take conventional treatments without hydroxychloroquine.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3
Time Frame: 3 days after randomization
|
3 days after randomization
|
|
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5
Time Frame: 5 days after randomization
|
5 days after randomization
|
|
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7
Time Frame: 7 days after randomization
|
7 days after randomization
|
|
The mortality rate of subjects at weeks 2
Time Frame: 14 days after randomization
|
14 days after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 14 days after randomization
|
14 days after randomization
|
|
|
The critical illness rate of subjects at weeks 2
Time Frame: 14 days after randomization
|
The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.
|
14 days after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Lung Diseases
- Bacterial Infections and Mycoses
- Mycoses
- Lung Diseases, Fungal
- Pneumocystis Infections
- COVID-19
- Pneumonia
- Pneumonia, Pneumocystis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
Other Study ID Numbers
- HC-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.